MSA-IL-2

MSA-IL-2 is an engineered recombinant fusion protein consisting of interleukin-2 (IL-2) fused to mouse serum albumin (MSA). This modification is designed to significantly extend the circulatory half-life of the cytokine, which naturally has a very short duration of action, thereby allowing for lower and less frequent dosing to achieve therapeutic concentrations while potentially reducing systemic toxicity. In preclinical research, MSA-IL-2 has been extensively studied in murine models of glioblastoma multiforme (GBM), such as the GL261 model. Research indicates that when combined with anti-PD-1 checkpoint blockade, MSA-IL-2 can clear established tumors and establish long-term immunological memory. Notably, this therapeutic effect has been shown to function independently of MHC class I restricted CD8+ T cell presentation, instead relying on CD4+ T cell activity and reversing GBM-associated immunosuppression.

Other names

mouse serum albumin-interleukin-2 fusion proteinextended half-life IL-2MSA-fused IL-2